TICKERNERD
Menu
BJDXBJDXHealthcare · Medical Devices

BJDX Stock Forecast: Bluejay Diagnostics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$0.90
−11.16% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 20 of 100 as at 12 Sept 2026 — in the weakest quartile.

Market cap
$928,449.00
Ticker Nerd rank
20 / 100
Median analyst target
—
Analysts covering
0
Revenue$0.0
Operating income−$2.3M
Net income−$2.3M
Free cash flow−$1.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.7%
1M
−16.1%
YTD
−66.4%
1Y
−84.7%
From 52W high
−93.6%
From 52W low
+7.8%
$1
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BJDX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Bluejay Diagnostics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
20 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
97
Accruals
73
Volatility
60
Momentum
33
Issuance
33
Growth
27
Revisions
25
Quality
10
Value
2

Size (97): Smaller than most of the companies we track.

Value (2): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BJDX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BJDX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$2$4$6$8$10$12$14Oct 25Jan 26Apr 26Jul 26BJDX

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 Aug 2023Dawson JamesDowngradeNeutral—
12 Jan 2022Dawson JamesInitiatesBuy$10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BJDX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BJDX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Bluejay Diagnostics, Inc. returned −84.7% against +17.5% for the S&P 500, dividends included.

BJDX vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150200Oct 25Jan 26Apr 26Jul 26BJDXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BJDX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Bluejay Diagnostics, Inc. (BJDX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 75% of US stocks

Price / sales
—
Price / book
0.2×

Cheaper than 89% of US stocks

EV / EBITDA
0.8×

Cheaper than 58% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−98.9%

Higher than 13% of US stocks

Return on assets
−51.1%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Bluejay Diagnostics, Inc. (BJDX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Bluejay Diagnostics, Inc. has a market value of $928K and an enterprise value of −$5.5M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$7.3M.

  • Free cash flow in the twelve months to 30 June 2026: −$6.2M.

  • Shares outstanding: 1.0M.

  • Trailing P/E: 0.0×; forward P/E: −2.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Bluejay Diagnostics, Inc. employs 6 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

BJDX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
BJDXBluejay Diagnostics, Inc.$928,449.00
20
NXLNexalin Technology, Inc.$4.0M
25
VVOSVivos Therapeutics, Inc.$3.7M
32
VTAKCatheter Precision, Inc.$3.3M
26
FEEDENvue Medical, Inc.$3.3M
23
POASPhaos Technology Holdings (Cayman) Ltd.$4.9M
2
ITOCiTonic Holdings Ltd.$5.2M
25

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Bluejay Diagnostics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BJDX news & analysis

Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets

GlobeNewsWire · 8 Sept 2026positive

Bluejay Diagnostics announced a partnership with Lovell Government Services to establish a federal distribution and co-marketing framework aimed at expanding access to U.S. federal healthcare markets, including the VA, DoD, and Military Health Systems, as well as other government healthcare channels.

Why it matters — This partnership could open new government distribution channels for Bluejay Diagnostics, potentially broadening its market reach within the federal healthcare sector.

Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization

GlobeNewsWire · 13 Aug 2026positive

Bluejay Diagnostics reported its financial results for the quarter ended June 30, 2026, and provided an update on its clinical, regulatory and manufacturing progress. The company said its strengthened balance sheet supports advancement of the Symphony™ IL-6 test toward regulatory submission and commercialization.

Why it matters — A BJDX watcher would care because the update addresses the company's clinical, regulatory and manufacturing progress toward bringing Symphony™ IL-6 to regulatory submission and commercialization.

FAQ

Frequently asked questions about BJDX stock

How does Ticker Nerd's model rank BJDX?

As at 12 Sept 2026, Bluejay Diagnostics, Inc. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).

What is the BJDX stock forecast for 2030?

No analyst covering Bluejay Diagnostics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BJDX are extrapolating price history, which says nothing about the business.

How has BJDX stock performed over the past year?

Bluejay Diagnostics, Inc. returned -84.7% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Bluejay Diagnostics, Inc. do?

Bluejay Diagnostics Inc. is a medical diagnostics company focused on rapid, near-patient testing solutions for critical care and other clinical settings.

What is the latest news on BJDX?

The most recent item we track (GlobeNewsWire, 8 Sept 2026): "Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets". Bluejay Diagnostics announced a partnership with Lovell Government Services to establish a federal distribution and co-marketing framework aimed at expanding access to U.S. federal healthcare markets, including the VA, DoD, and Military Health Systems, as well as other government healthcare channels.

Company

About Bluejay Diagnostics, Inc.

Bluejay Diagnostics Inc. is a medical diagnostics company focused on rapid, near-patient testing solutions for critical care and other clinical settings. Its core Symphony platform combines an analyzer and single-use cartridges to process whole blood and detect key biomarkers, supporting timely assessment of inflammation, infection, and cardiac conditions. The company’s current product development includes the Symphony IL-6 test for monitoring disease progression in critical care, along with additional assays targeting myocardial infarction and congestive heart failure. Bluejay Diagnostics also develops point-of-care diagnostic products designed to give healthcare providers faster, practical insights at the bedside. Headquartered in Acton, Massachusetts, Bluejay Diagnostics Inc. serves the healthcare market through technologies aimed at improving diagnostic workflows and supporting informed clinical decision-making.

CEO Mr. Indranil Dey · 6 employees · United States · https://bluejaydx.com